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Objective: To examine time trends of survival and mortality of ovarian cancer in the central 
and northern Denmark regions during the period 1998–2009.
Study design and setting: We conducted a cohort study including women recorded with 
a first-time diagnosis of ovarian cancer in the Danish National Registry of Patients (DNRP) 
between 1998 and 2009. Patients were followed for survival through the Danish Civil Registration 
System. We determined survival stratified by age, and used Cox proportional hazard regression 
analyses to obtain mortality rate ratios (MRRs) to assess changes over time.
Results: We found no improvement in overall ovarian cancer survival between 1998 and 2009. 
One-year survival was 71% in 1998–2000 and 68% in 2007–2009. Three-year survival declined 
from 48% in 1998–2000 to 46% in 2007–2009 (predicted), and 5-year survival declined from 
40% in 1998–2000 to 37% in 2007–2009 (predicted). Compared with the period 1998–2000, 
the age-adjusted 1-year MRR was 1.05 (95% confidence interval CI: 0.86–1.28) for the period 
2007–2009, and the predicted age-adjusted 3- and 5-year MRRs were 0.96 (95% CI: 0.83–1.12) 
and 0.99 (95% CI: 0.86–1.14), respectively. Results are not adjusted for tumor stage as this 
information was not available. We also observed a decline in the annual number of incident 
ovarian cancer patients during the study period, most pronounced in the youngest age group.
Conclusion: The survival of ovarian cancer patients did not improve during the study period. 
This lack of improvement contrasts with the national cancer strategies implemented during this 
last decade, focusing on improving the survival of ovarian cancer patients.
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Introduction
Ovarian cancer is the eighth most commonly diagnosed cancer in Danish women, 
with 577 new cases diagnosed in 2009, corresponding to an incidence rate of 19 per 
100,000 women per year.1 Lack of both clearly defined symptoms and knowledge 
of the natural history of the tumor makes screening and early diagnosis of ovarian 
cancer difficult, resulting in detection at more advanced stages with poor prognosis. 
A Nordic study following ovarian cancer patients diagnosed in 1964 to 2003 to end of 
20062 found declines in ovarian cancer incidence and mortality in all Nordic countries. 
Throughout the period, however, survival remained lower and mortality rates higher 
in Denmark than in the other Nordic countries. In patients diagnosed in 1999 to 
2003, 5-year relative survival was 33% in Denmark compared with 40% in the other 
Nordic countries. This is consistent with previous studies showing lower survival in 
Danish ovarian cancer patients compared with patients in other European countries.3–5 
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ovarian cancer in six different countries (Australia, Canada, 
Norway, Sweden, UK, and Denmark) during 1995–2007 
through population-based cancer registries. Danish ovarian 
cancer patients had lower relative 1- and 5-year survival than 
patients from all other countries except the UK. So far, the 
reasons for this poorer survival of Danish ovarian cancer 
patients remain unknown.
Primary radically intended surgery and postoperative 
chemotherapy is the main treatment for ovarian cancer.7,8 
Until 1998, surgery of gynecological cancer in Denmark took 
place at general departments of gynecology and obstetrics 
(over 40 different departments).9 In 2000 and 2005, the first 
and second Danish Cancer Control Plans were initiated.10 The 
launched initiatives focused on reduction of diagnostic delay, 
treatment restricted to specialized centers, and establishment 
of multidisciplinary cancer groups.
Because of the poor prognosis of ovarian cancer in 
  Denmark, it is important to monitor survival as an indicator 
of quality of treatment. We therefore used population-based 
hospital discharge registries to examine changes in mortality 
and survival of ovarian cancer patients diagnosed between 
1998 and 2009. We thereby extended a previous study from 
our regions, covering ovarian cancer survival in the period 
1985–2004.11
Materials and methods
We conducted this study in the central and the northern 
Denmark regions, with a combined population of 
1.8 million persons. The National Health Service provides 
tax-supported health care for all inhabitants of Denmark, 
guaranteeing free access to hospitals. Virtually no ovarian 
cancer patients were treated in private hospitals during the 
study period.
Identification of ovarian cancer patients
hospital discharge registries
Through the Danish National Registry of Patients (DNRP), 
we identified all patients who had a first-time hospitalization 
with ovarian cancer in the period January 1, 1998 through 
December 31, 2009. The DNRP contains information about 
all admissions from nonpsychiatric hospitals in Denmark 
since 1977.12 Outpatient and emergency room visits at hos-
pitals have been included since 1995. This registry includes 
information on civil registration number, dates of admission 
and discharge, surgical procedure(s) performed, and up to 20 
diagnoses from each hospital contact. Diagnoses have been 
classified according to the International Classification of 
Diseases 8th edition (ICD-8) until the end of 1993 and 10th 
edition (ICD-10) thereafter. Surgical procedures have been 
classified according to a Danish classification system until the 
end of 1995 and according to a Danish version of the Nordic 
Classification of Surgical Procedures (NCSP) thereafter.
The ICD-10 codes used to identify ovarian cancer were 
C56.x and the ICD-8 codes used were 183.00–183.09.
The Danish Civil registration System
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit personal identification number 
to all Danish citizens.13 This number, unique to each Danish 
resident, is used in all Danish registries, allowing unambigu-
ous individual-level data linkage. From the Civil Registration 
System we also obtained information on vital status (dead or 
alive), date of death, and residence for all cancer patients.
Statistical analysis
Survival
We followed each patient from date of cancer diagnosis 
until emigration, death, or June 25, 2010, whichever came 
first. To visualize crude survival we constructed Kaplan–
Meier curves stratified according to period of diagnosis 
(1998–2000, 2001–2003, 2004–2006, and 2007–2009). 
We estimated 1-, 3-, and 5-year survival. In the latter periods, 
we estimated 3- and 5-year survival using a hybrid analysis in 
which survival was estimated using the survival experience 
of patients in the previous periods.14
We used Spearmans’ rank correlation to test for trend in 
the age distribution of the incident ovarian cancer cases.
Mortality
To compare mortality over time we used Cox proportional 
hazards regression analysis, with 1998–2000 as the reference 
period to estimate 1-, 3-, and 5-year mortality rate ratios 
(MRRs) and corresponding 95% confidence intervals (CIs), 
adjusting for age group. The survival was estimated within 
three age strata: 15–49 years, 50–69 years, and 70+.
Analyses were performed using SAS version 9.2 (SAS 
Institute Inc, Cary, NC).
Results
We identified a total of 2541 women who were diagnosed with 
ovarian cancer for the first time between 1998 and 2009.
Age characteristics of ovarian cancer 
patients
The median age was 63 (range 15–103) years over all time 
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presented in Table 1. The prevalence of women younger than 
50 years of age decreased from 20% to 10% during the study 
period (test for trend, P , 0.001). During the study period, 
the absolute number of women diagnosed with ovarian cancer 
fell from 664 patients in 1998–2000 to 616 in 2007–2009.
Survival
The overall survival curves for the four periods showed only 
small changes in survival over the years (Figure 1).   One-year 
survival decreased from 71% to 68% during the period 
1998–2009. This corresponded to an age-adjusted MRR 
of 1.05 (95% CI 0.86–1.28). The predicted 3- and 5-year 
survival for women diagnosed in 2007–2009 were 46% and 
37%, respectively, which was also a decrease in survival 
during the period (Table 2). The 3- and 5-year MRRs for 
2007–2009 were predicted to be 0.96 (95% CI 0.83–1.12) 
and 0.99 (95% CI 0.86–1.14), respectively, compared with 
1998–2000.
For all three age groups, 1-year survival remained 
virtually unchanged throughout the study period. For the 
youngest women (aged 15–49 years), the 1-year survival 
was 92%. For women aged 50–69 years and 70 years or 
older, 1-year survival was 79% in 1998–2000 and 79% in 
2007–2009, and 49% and 48%, respectively.
A similar pattern was seen for 3- and 5-year survival 
(Table 3).
Discussion
In this population-based follow-up study, we found that the 
survival after ovarian cancer diagnosis remained almost 
unchanged during the period 1998–2009. Not surprisingly, 
the youngest age group had better survival than the older 
age groups, but within each age group, survival was almost 
unchanged over the years.
Our data thus extend findings from four previous Danish 
studies. Three studies, based on data from the Danish Cancer 
Registry, found improved 5-year survival over the period 
1943–1987 (22.3% versus 30.4%)15 but no improvement 
in survival between 1973 and 1978 and between 1981 and 
1986,16 and only a slight increase in survival from 1978 to 
2002.17 A fourth Danish study, based on hospital discharge 
registries, similarly found a 5-year survival of 30% in the 
period 1985–1989, with a 5-year adjusted MRR of 0.8 
(95% CI 0.72–0.90) from 1985 to 2004.11 Still, the overall 
improvement in ovarian cancer survival during the last 
decades has been limited.
Our study was large and included all ovarian cancer 
patients from a well defined area covering approximately 
30% of the Danish population. We accomplished complete 
vital status follow-up by using the Civil Registry System. 
Table 1 Number of women with a first-time diagnosis of ovarian 
cancer in three age groups (1998–2009)
Age group Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
15–49 years 135 (20%) 134 (21%) 85 (14%) 64 (10%)
50–69 years 298 (45%) 304 (47%) 329 (53%) 310 (50%)
70+ 231 (35%) 206 (32%) 203 (33%) 242 (39%)
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Data on cancer in Denmark are usually extracted from the 
nationwide Danish Cancer Registry because of the high 
  completeness and accuracy of data in this registry.18,19 
However, use of data from the Cancer Registry would not 
allow us to compute updated estimates from the most recent 
calendar years. Thus, data from the Cancer Registry are not 
optimal for an ongoing quality assessment of conceivable 
recent improvements in ovarian cancer treatment. Patient 
registries may, however, be affected by some degree of 
misclassification of ovarian cancer diagnoses. Malignant 
ovarian tumors include invasive tumors and borderline 
tumors. The ovarian cancer diagnoses (including borderline 
tumors) have previously been validated by comparing data 
from the hospital registry with data from the Danish Cancer 
Registry.20 Ovarian cancer diagnoses had a completeness 
of 96% in the hospital discharge registry, and the positive 
predictive value was 87%. Before 2001, the DNPR com-
prised no specific code for borderline tumors, and these 
could therefore not be separated from invasive tumors. 
In a previous Danish study by Tetsche et al, borderline 
tumors comprised 18% of ovarian cancers registered during 
1994–2003.20 Patients with borderline tumors have a 5-year 
survival of 86%,21 which is far better than that for patients 
with invasive disease. When interpreting our results from 
before 2001, it is therefore important to be aware that inclu-
sion of borderline tumors will inflate the survival estimates 
compared with estimates based purely on invasive tumors, 
and inclusion of borderline tumors in the first part of our 
Table 2 One-, 3-, and 5-year survival and Mrrs, with the period 1998–2000 as a reference
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 664 644 617 616
Median age (years) 63 61 64 66
1 year
Survival 71% (68%–74%) 73% (70%–77%) 71% (67%–74%) 68% (64%–71%)
Mrr 1 (reference) 0.92 (0.74–1.12) 1.04 (0.85–1.27) 1.15 (0.94–1.40)
Mrra 1 (reference) 0.95 (0.77–1.17) 1.04 (0.85–1.27) 1.05 (0.86–1.28)
3 year
Survival 48% (44%–51%) 50% (46%–53%) 50% (46%–54%) 46% (42%–50%)b
Mrr 1 (reference) 0.95 (0.81–1.10) 0.95 (0.81–1.11) 1.05 (0.90–1.22)b
Mrra 1 (reference) 0.96 (0.83–1.12) 0.91 (0.78–1.06) 0.96 (0.83–1.12)b
5 year
Survival 40% (36%–44%) 40% (36%–44%) 41% (37%–44%)b 37% (34%–41%)b
Mrr 1 (reference) 0.99 (0.86–1.13) 0.98 (0.85–1.13)b 1.07 (0.93–1.23)b
Mrra 1 (reference) 1.00 (0.87–1.15) 0.94 (0.82–1.08)b 0.99 (0.86–1.14)b
Notes: Estimates are presented with 95% confidence intervals; aadjusted for age; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.
Table 3 One-, 3-, and 5-year cumulative survival for ovarian cancer patients in three different age groups
Age (years) Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
15–49
  number of cancer patients 135 134 85 64
  1-year survival 92% (86%–95%) 92% (86%–95%) 92% (84%–96%) 92% (82%–97%)
  3-year survival 78% (70%–84%) 79% (71%–85%) 85% (75%–91%) 80% (69%–87%)a
  5-year survival 71% (62%–78%) 71% (62%–78%) 72% (61%–80%)a 69% (57%–78%)a
50–69
  number of cancer patients 298 304 329 310
  1-year survival 79% (74%–83%) 79% (74%–83%) 78% (73%–82%) 79% (73%–83%)
  3-year survival 52% (46%–58%) 51% (45%–56%) 53% (48%–59%) 52% (47%–58%)a
  5-year survival 43% (37%–48%) 41% (36%–47%) 44% (38%–49%)a 43% (37%–48%)a
70+
  number of cancer patients 231 206 203 242
  1-year survival 49% (43%–56%) 53% (46%–60%) 50% (43%–57%) 48% (41%–54%)
  3-year survival 24% (19%–30%) 28% (22%–34%) 30% (24%–36%) 28% (22%–34%)a
  5-year survival 18% (13%–23%) 17% (12%–22%) 22% (17%–28%)a 20% (15%–26%)a
Notes: Estimates are presented with 95% confidence intervals in parentheses; apredicted values.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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study period could thus mask a potential survival benefit 
in patients with invasive tumors. We observed a decline 
in the absolute number of patients with an ovarian cancer 
diagnosis after 2000, which is consistent with inclusion of 
some borderline tumors before then.
However, factors, not related to the health care system, 
can also influence survival data on ovarian cancer patients.22 
The outcome of ovarian cancer may be influenced by factors 
such as aggressiveness of the tumor as it progresses along 
its clinical course, presence of other diseases (comorbidity), 
quality and accessibility/availability of diagnostic tests, and 
organization of health system.23 Tumor stage at diagnosis 
has been identified as an important prognostic factor.15 
Unfortunately, we had no information about tumor stage in 
our study, but during our study period, increasing use of, and 
better access to, diagnostic ultrasound, magnetic resonance, 
and computed tomography scanning may have resulted in 
earlier diagnosis, but these methods are implemented only 
when patients present with symptoms, and do not serve as a 
screening method contributing significantly to diagnosis at 
an earlier disease stage.
The impact of comorbid conditions on ovarian cancer 
survival has been investigated in several studies,24–26 and 
decreased survival has been found to be associated with 
presence of comorbidity. Still, we do not expect increasing 
prevalence of comorbidity among ovarian cancer patients to 
entirely explain our lack of improvement in survival. In 2000 
and 2005, the first and second Danish Cancer   Control 
Plans were initiated.10 The launched initiatives focused on 
reduction of diagnostic delay and establishment of multi-
disciplinary cancer groups. During our study period, the 
surgical treatment of ovarian cancer in Denmark has been 
centralized.9 In 2008, the number of departments treating 
stage III and IV ovarian cancer was reduced to six high-
volume departments. The National Board of Health recom-
mends further reduction to four high-volume departments.9 
The proposed centralization has been implemented only in 
the recent years, accomplished by more extensive, radical 
surgery. In our study, these initiatives have not yet resulted 
in better survival of ovarian cancer patients living in central 
and northern Denmark.
Conclusion
The survival of ovarian cancer patients has not improved 
during the study period. This lack of improvement contrasts 
with the national cancer strategies implemented during this 
last decade focusing on improving the survival of ovarian 
cancer patients.
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